Affiliation:
1. The Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health Guizhou Medical University Guiyang Guizhou China
2. Department of Infection Guiyang Public Health Clinical Center Guiyang Guizhou China
Abstract
AbstractBackgroundProspective studies examining long‐term therapeutic outcomes of the Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) regimen in human immunodeficiency virus (HIV) infection remain limited. This study assessed the actual efficacy and safety of BIC/FTC/TAF in HIV‐infected individuals in southwest China.MethodsThis was a single‐center, prospective study enrolling ART‐naïve (n = 32) and ART‐experienced (n = 177) HIV‐infected patients administered BIC/FTC/TAF treatment between March 2022 and August 2022. The data were collected until February 28, 2023. Virological reactions and adverse events to the treatment were recorded, and patient subjective feelings in the form of Electronic Patient Reporting Outcome (ePRO) were collected. The primary endpoint was the rate of patients with HIV viral load <50 copies/mL at Week 24.ResultsAt Week 24, 87.5% and 95.5% of ART‐naïve and ART‐experienced HIV patients had a viral load <50 copies/mL, respectively. CD4 cell counts in ART‐naïve and ART‐experienced patients increased significantly by 163.5 cells/μL (p = .002) and 55.0 cells/μL (p = .022), respectively. By Week 24, no patients had discontinued the BIC/FTC/TAF treatment due to adverse events. Based on ePRO data, ART‐naïve and ART‐experienced patients at Week 24 had stable disease symptom burden, quality of life, and depression level after treatment with BIC/FTC/TAF.ConclusionBIC/FTC/TAF reduces the viral load in ART‐naïve patients with high viral load as well as ART‐experienced patients with residual viremia. The patient's subjective experience was maintained stable after treatment with BIC/FTC/TAF. This study also revealed a very low incidence for BIC/FTC/TAF drug‐related side effects.
Subject
Immunology,Immunology and Allergy
Reference23 articles.
1. Treatment Adherence And Persistence Among HIV-1 Patients Newly Starting Treatment
2. Patient‐reported outcome: comparison between the domestic and the global application progress;Chengchen L;Chin J Drug Eval,2015
3. Application of ePRO assessing efficacy in clinical trials of new drugs;Xiaoxian L;Drug Eval Res,2021
4. Chinese guidelines for the prevention and treatment of dyslipidemia in adults (2016 revision);Junren Z;Chin Circ J,2016
5. Development and validation of a self-completed HIV symptom index
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献